Seattle Genetics Inc. (SGEN)

55.43
0.20 0.36
NASDAQ : Health Technology
Prev Close 55.23
Open 55.11
Day Low/High 55.11 / 55.92
52 Wk Low/High 45.31 / 68.59
Volume 331.04K
Avg Volume 899.30K
Exchange NASDAQ
Shares Outstanding 158.22M
Market Cap 8.76B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 26, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 26, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets.

Http://www.astellas.com/en

Http://www.astellas.com/en

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc.

Seattle Genetics Appoints Dr. Alpna Seth To Board Of Directors

Seattle Genetics Appoints Dr. Alpna Seth To Board Of Directors

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth, Ph.

Seattle Genetics To Present At The Barclays Global Healthcare Conference 2018

Seattle Genetics To Present At The Barclays Global Healthcare Conference 2018

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.

Seattle Genetics Completes Acquisition Of Cascadian Therapeutics

Seattle Genetics Completes Acquisition Of Cascadian Therapeutics

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc.

Seattle Genetics Completes Tender Offer For All Shares Of Cascadian Therapeutics

Seattle Genetics Completes Tender Offer For All Shares Of Cascadian Therapeutics

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub", for all of the shares of common stock of Cascadian Therapeutics, Inc.

Seattle Genetics Initiates New Phase 1 Study In Relapsed Or Refractory Multiple Myeloma

Seattle Genetics Initiates New Phase 1 Study In Relapsed Or Refractory Multiple Myeloma

Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOI, ATSG, CKH, CRM, DDS, EQBK, FSTR, GNK, NEWM, OAS, RDC, RRC, TCMD, UHS, WTW Downgrades: AHGP, AMED, AXE, CTRE, CULP, DOC, EMKR, GLW, HABT, IT, KBR, RP, SGEN, SPOK, SWM, TACO, UGP, UTHR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Seattle Genetics To Present At Cowen And Company 38th Annual Health Care Conference

Seattle Genetics To Present At Cowen And Company 38th Annual Health Care Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.

Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period

Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") with respect to Seattle Genetics' proposed acquisition of...

Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other...

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics, Inc.

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics, Inc.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc.

Seattle Genetics Reports Fourth Quarter And Year 2017 Financial Results

Seattle Genetics Reports Fourth Quarter And Year 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017.

Seattle Genetics Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

Seattle Genetics Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle...

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.

Seattle Genetics Announces Proposed Public Offering Of Common Stock

Seattle Genetics Announces Proposed Public Offering Of Common Stock

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of $550.

Seattle Genetics To Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program To Its Oncology Pipeline

Seattle Genetics To Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program To Its Oncology Pipeline

Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc.

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval For CD30-Positive Cutaneous T-Cell Lymphoma After At Least One Prior Systemic Therapy

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval For CD30-Positive Cutaneous T-Cell Lymphoma After At Least One Prior Systemic Therapy

Seattle Genetics, Inc. (Nasdaq: SGEN) reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2017 Financial Results On February 6, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2017 Financial Results On February 6, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets.

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Jim Cramer is bullish on Deere & Co., Analog Devices, Mercadolibre, Teradyne, AbbVie, Antero Midstream Partners.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Seattle Genetics Highlights Leadership In Expanding Field Of Antibody-Drug Conjugates (ADCs) At The 36th Annual J.P. Morgan Healthcare Conference

Seattle Genetics Highlights Leadership In Expanding Field Of Antibody-Drug Conjugates (ADCs) At The 36th Annual J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted today the progress of its pipeline of antibody-drug conjugates (ADCs) at the 36 th Annual J.

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.

TheStreet Quant Rating: D+ (Sell)